These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36905966)
1. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor. Chauhan J; Yoshioka M; Pogash S; Strovel JW; Fletcher S Bioorg Med Chem Lett; 2023 Apr; 86():129220. PubMed ID: 36905966 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy. Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760 [TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Benzo[ Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809 [TBL] [Abstract][Full Text] [Related]
6. Discovery of BET specific bromodomain inhibitors with a novel scaffold. Pandit N; Yoo M; Hyun Park T; Kim J; Mi Kim S; Myung Lee K; Kim Y; Min Bong S; Il Lee B; Jung KY; Hoon Park C Bioorg Med Chem; 2022 Oct; 72():116967. PubMed ID: 36099719 [TBL] [Abstract][Full Text] [Related]
7. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. Zhao Y; Bai L; Liu L; McEachern D; Stuckey JA; Meagher JL; Yang CY; Ran X; Zhou B; Hu Y; Li X; Wen B; Zhao T; Li S; Sun D; Wang S J Med Chem; 2017 May; 60(9):3887-3901. PubMed ID: 28463487 [TBL] [Abstract][Full Text] [Related]
8. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196 [TBL] [Abstract][Full Text] [Related]
9. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Imayoshi N; Yoshioka M; Chauhan J; Nakata S; Toda Y; Fletcher S; Strovel JW; Takata K; Ashihara E Biochem Biophys Res Commun; 2017 Mar; 484(2):262-268. PubMed ID: 28115161 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor. Hagihara S; Ishizawa K; Soga K; Honjo T; Takai S; Kawano Y; Kikuchi M; Nishidate A; Matsumoto F; Murase M; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J Bioorg Med Chem Lett; 2024 Sep; 109():129849. PubMed ID: 38876177 [TBL] [Abstract][Full Text] [Related]
11. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490 [TBL] [Abstract][Full Text] [Related]
13. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496 [TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403 [TBL] [Abstract][Full Text] [Related]
17. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor. Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718 [TBL] [Abstract][Full Text] [Related]
19. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Kulikowski E; Rakai BD; Wong NCW Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459 [TBL] [Abstract][Full Text] [Related]
20. Structure-Based Discovery and Optimization of Furo[3,2- Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]